Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have received an average rating of “Buy” from the twenty-four ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $187.78.
Several equities analysts have commented on SRPT shares. Piper Jaffray Companies set a $185.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Friday, September 27th. ValuEngine upgraded shares of Sarepta Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Citigroup decreased their price objective on shares of Sarepta Therapeutics from $185.00 to $180.00 and set a “buy” rating on the stock in a report on Friday, September 27th. Cantor Fitzgerald decreased their price target on shares of Sarepta Therapeutics from $231.00 to $175.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 20th. Finally, Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $202.00 to $181.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 20th.
In other news, Director M Kathleen Behrens acquired 2,500 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was acquired at an average price of $87.98 per share, with a total value of $219,950.00. Following the completion of the transaction, the director now directly owns 123,167 shares of the company’s stock, valued at approximately $10,836,232.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard Barry acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The shares were purchased at an average cost of $87.49 per share, with a total value of $437,450.00. Following the transaction, the director now directly owns 3,183,756 shares of the company’s stock, valued at $278,546,812.44. The disclosure for this purchase can be found here. Insiders purchased 14,500 shares of company stock worth $1,327,480 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.
NASDAQ SRPT traded up $0.05 during trading on Thursday, reaching $97.46. 1,080,200 shares of the stock traded hands, compared to its average volume of 1,222,005. Sarepta Therapeutics has a fifty-two week low of $72.05 and a fifty-two week high of $158.80. The firm has a market cap of $7.26 billion, a price-to-earnings ratio of -17.85 and a beta of 2.19. The stock’s 50-day moving average price is $86.25 and its 200 day moving average price is $112.71. The company has a quick ratio of 7.84, a current ratio of 6.31 and a debt-to-equity ratio of 0.49.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by ($0.35). Sarepta Therapeutics had a negative net margin of 169.87% and a negative return on equity of 55.44%. The company had revenue of $99.04 million during the quarter, compared to analyst estimates of $98.49 million. During the same quarter in the prior year, the firm earned ($1.15) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 26.2% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics will post -6 EPS for the current fiscal year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Recommended Story: Bid-Ask Spread
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.